Nanosonics Limited, together with its subsidiaries, operates as an infection prevention company in Australia and internationally.
No risks detected for NAN from our risk checks.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$6.49|
|52 Week High||AU$4.89|
|52 Week Low||AU$8.25|
|1 Month Change||-3.99%|
|3 Month Change||11.13%|
|1 Year Change||12.28%|
|3 Year Change||80.78%|
|5 Year Change||91.45%|
|Change since IPO||691.46%|
Recent News & Updates
Returns Are Gaining Momentum At Nanosonics (ASX:NAN)
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'll...
|NAN||AU Medical Equipment||AU Market|
Return vs Industry: NAN exceeded the Australian Medical Equipment industry which returned 5.3% over the past year.
Return vs Market: NAN underperformed the Australian Market which returned 24.4% over the past year.
Stable Share Price: NAN is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: NAN's weekly volatility (7%) has been stable over the past year.
About the Company
Nanosonics Limited, together with its subsidiaries, operates as an infection prevention company in Australia and internationally. The company engages in the manufacturing and distribution of the trophon ultrasound probe disinfector, and its associated consumables and accessories; and research, development, and commercialization of infection control and decontamination products and related technologies. It provides trophon2, an ultrasound probe high level disinfection device; trophon EPR, a low temperature high level disinfection solution for intra-cavity ultrasound probes; and Nanosonics AuditPro, an infection control workflow compliance management solution.
Nanosonics Fundamentals Summary
|NAN fundamental statistics|
Is NAN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NAN income statement (TTM)|
|Cost of Revenue||AU$22.70m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.028|
|Net Profit Margin||8.32%|
How did NAN perform over the long term?See historical performance and comparison
Is Nanosonics undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: NAN (A$6.49) is trading above our estimate of fair value (A$3.67)
Significantly Below Fair Value: NAN is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: NAN is poor value based on its PE Ratio (228.3x) compared to the Australian Medical Equipment industry average (13.3x).
PE vs Market: NAN is poor value based on its PE Ratio (228.3x) compared to the Australian market (19.1x).
Price to Earnings Growth Ratio
PEG Ratio: NAN is poor value based on its PEG Ratio (8.3x)
Price to Book Ratio
PB vs Industry: NAN is overvalued based on its PB Ratio (14.4x) compared to the AU Medical Equipment industry average (4.5x).
How is Nanosonics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NAN's forecast earnings growth (27.4% per year) is above the savings rate (1.9%).
Earnings vs Market: NAN's earnings (27.4% per year) are forecast to grow faster than the Australian market (11.4% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: NAN's revenue (15.1% per year) is forecast to grow faster than the Australian market (5.3% per year).
High Growth Revenue: NAN's revenue (15.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NAN's Return on Equity is forecast to be low in 3 years time (13.5%).
How has Nanosonics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NAN has high quality earnings.
Growing Profit Margin: NAN's current net profit margins (8.3%) are lower than last year (10.1%).
Past Earnings Growth Analysis
Earnings Trend: NAN's earnings have declined by 13.5% per year over the past 5 years.
Accelerating Growth: NAN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: NAN had negative earnings growth (-15.4%) over the past year, making it difficult to compare to the Medical Equipment industry average (74.9%).
Return on Equity
High ROE: NAN's Return on Equity (6.3%) is considered low.
How is Nanosonics's financial position?
Financial Position Analysis
Short Term Liabilities: NAN's short term assets (A$142.3M) exceed its short term liabilities (A$19.5M).
Long Term Liabilities: NAN's short term assets (A$142.3M) exceed its long term liabilities (A$7.2M).
Debt to Equity History and Analysis
Debt Level: NAN is debt free.
Reducing Debt: NAN had no debt 5 years ago.
Debt Coverage: NAN has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: NAN has no debt, therefore coverage of interest payments is not a concern.
What is Nanosonics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NAN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NAN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NAN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NAN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NAN's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Michael C. Kavanagh, BSc, MBA (Advanced,) has been the Chief Executive Officer and President of Nanosonics Limited since October 21, 2013 and served as its Managing Director. Mr. Kavanagh served as a S...
CEO Compensation Analysis
Compensation vs Market: Michael's total compensation ($USD1.03M) is about average for companies of similar size in the Australian market ($USD1.30M).
Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.
Experienced Management: NAN's management team is considered experienced (2.7 years average tenure).
Experienced Board: NAN's board of directors are considered experienced (4.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Nanosonics Limited's employee growth, exchange listings and data sources
- Name: Nanosonics Limited
- Ticker: NAN
- Exchange: ASX
- Founded: 2000
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: AU$1.958b
- Shares outstanding: 301.62m
- Website: https://www.nanosonics.com.au
Number of Employees
- Nanosonics Limited
- 14 Mars Road
- Lane Cove
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/26 08:05|
|End of Day Share Price||2021/09/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.